Health Care Equipment

Sysmex

Sysmex released FY2026 annual earnings on May 14 After-Market EST, actual revenue USD 3.295 B (forecast USD 3.135 B), actual EPS USD 0.3748

Sysmex released FY2026 Q4 earnings on May 14 After-Market EST, actual revenue USD 869.4 M (forecast USD 870.4 M), actual EPS USD 0.0177

Sysmex to release FY2026 earnings on May 14 After-Market EST, forecast revenue USD 3.145 B

Sysmex released FY2026 9 Months Earnings on February 12, 2026 (EST) with actual revenue of USD 2.406 B and EPS of USD 0.357

Sysmex released FY2026 Q3 earnings on February 12 (EST), actual revenue USD 822.16 M (forecast USD 820.54 M), actual EPS USD 0.1504

Sysmex to release FY2026 Q3 earnings report on February 11 during market hours EST, forecast revenue USD 810.63 M

Sysmex released FY2026 Q2 earnings on November 5, 2025 (EST), with actual revenue of USD 853.09 M (forecast USD 899.75 M), actual EPS USD 0.1561

Sysmex released FY2026 Semi-Annual earnings on November 5, 2025 (EST), actual revenue USD 1.585 B (forecast USD 1.596 B), actual EPS USD 0.2079

Sysmex to release FY2026 Q2 earnings report on November 4, 2025, during market hours EST, with forecast revenue of USD 872.99 M

Sysmex released FY2026 Q1 earnings on August 6 After-Market EST, actual revenue USD 730.4 M (forecast USD 811.54 M), actual EPS USD 0.0504

Sysmex to Release FY2026 Q1 Earnings on August 6, 2025 After-Market EST, Forecast Revenue USD 793.94 M

Terumo BCT (ADR) Receives FDA Approval

Terumo and Osaka University Collaborate on Neurological Disease Diagnosis

Terumo Reports Record Sales for Fiscal 2025

Sysmex released FY2025 Q4 earnings on May 14 (EST), actual revenue USD 946.73 M (forecast USD 992.85 M), actual EPS USD 0.1183

Sysmex released FY2025 Annual Earnings on May 14 (EST), actual revenue USD 3.335 B (forecast USD 3.457 B), actual EPS USD 0.5642

Terumo Corp (ADR) reports 10.2% net sales growth in FY 2025

Terumo (ADR) and Gaudi Clinical Form Cell Regeneration Collaboration

Sysmex to Release FY2025 Annual Earnings on May 13, 2025 (EST), Forecast Revenue USD 3.572 B

Sysmex (ADR) Sees Massive Increase in Short Positions

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

Silexion Therapeutics

GCL Global

MetaVia

MicroAlgo

Vida Global

Tradr 2X Long XNDU Daily ETF

6869

SSMXY

The Hematology Analyzers and Reagents Market is projected to grow from USD 7.57 billion in 2026 to USD 10.33 billion by 2031, at a CAGR of 6.4%. The Asia Pacific region is expected to witness the highest growth rate, driven by increasing demand for advanced diagnostic tools and rising prevalence of blood-related diseases. The blood cancer segment is anticipated to dominate the market, accounting for 34% of revenue share in 2025. Key players include Sysmex Corporation, Danaher Corporation, and Siemens Healthineers.

prnewswire

Sysmex Corporation

Siemens Healthineers AG

Danaher

10:15 ETHematology Analyzers and Reagents Market worth $10.33 billion by 2031 | MarketsandMarkets™

Sysmex (OTCMKTS:SSMXY) is set to release its quarterly earnings on May 13, with analysts expecting earnings of $0.0372 per share and revenue of $862.45 million. In its last report, Sysmex posted $0.15 EPS, exceeding estimates. The stock opened at $8.42, with a market cap of $5.30 billion. Citigroup downgraded Sysmex from "strong-buy" to "hold," with a consensus rating of "hold" among analysts. Sysmex specializes in in vitro diagnostic solutions and has a diverse product portfolio.

Market Beat

Citigroup

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Sysmex (SSMXY) Projected to Post Quarterly Earnings on Wednesday

Sysmex Corporation (OTCMKTS:SSMXY) reached a new 52-week low of $8.15 during trading, down from a previous close of $8.69. Citigroup downgraded the stock from "strong-buy" to "hold." Currently, Sysmex has an average rating of "hold" from analysts, with one buy and two hold ratings. The company reported $0.15 EPS for the last quarter, exceeding estimates, and had revenue of $837.32 million. Sysmex specializes in in vitro diagnostic solutions and has a market cap of $5.13 billion.

Sysmex (OTCMKTS:SSMXY) Reaches New 12-Month Low  - Here's What Happened

Sysmex Corporation ADR (OTCMKTS:SSMXY) experienced a significant increase in short interest in April, rising 465.6% to 495,062 shares as of April 15th. This represents approximately 0.1% of the company's shares. The short-interest ratio is currently 0.9 days based on an average daily volume of 527,925 shares. Citigroup downgraded Sysmex from a "strong-buy" to a "hold" rating. The stock traded at $8.71, with a market cap of $5.48 billion and a P/E ratio of 18.15. Analysts forecast earnings per share of 0.44 for the current fiscal year.

Sysmex Corporation ADR (OTCMKTS:SSMXY) Short Interest Update

Sysmex (OTCMKTS:SSMXY) has updated its FY 2025 earnings guidance, projecting EPS of 0.430 and revenue of $3.2 billion, below the consensus estimate of $3.3 billion. Following the announcement, Sysmex's stock fell 9.6% to $8.52. The company reported a net margin of 9.32% and a return on equity of 9.86% in its last earnings report. Sysmex specializes in in vitro diagnostic solutions and has a market cap of $5.36 billion.

Sysmex (OTCMKTS:SSMXY) Updates FY 2025 Earnings Guidance

Sysmex(SSMXY.US)

10:15 ETHematology Analyzers and Reagents Market worth $10.33 billion by 2031 | MarketsandMarkets™

Sysmex (SSMXY) Projected to Post Quarterly Earnings on Wednesday

Sysmex (OTCMKTS:SSMXY) Reaches New 12-Month Low - Here's What Happened

Sysmex Corporation ADR (OTCMKTS:SSMXY) Short Interest Update

Sysmex (OTCMKTS:SSMXY) Updates FY 2025 Earnings Guidance